Achieving lipid targets in primary care settings

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Current clinical practice struggles to achieve optimal low-density lipoprotein cholesterol (LDL-C) levels in many patients.
• Residual cardiovascular risk persists despite achieving LDL-C targets, influenced by triglycerides, high-density lipoprotein cholesterol (HDL-C), and LDL particle characteristics.

Discussion:

• Statins are the primary therapy for lipid disorders, with other agents used for intolerance or suboptimal response.
• Multifactorial treatment strategies incorporating statins demonstrate efficacy in reducing cardiovascular and residual risks.
• The clinical utility of emerging lipid-lowering therapies is yet to be determined.

Key Insights:

• Suboptimal LDL-C goal attainment highlights a gap in current lipid management.
• Persistent residual risk factors (triglycerides, HDL-C quality/quantity, small dense LDL) indicate the need for comprehensive risk assessment.
• Combination therapy and novel agents are crucial for addressing complex dyslipidemias.

Outlook:

• Further research is needed to establish the role of novel lipid therapies in clinical practice.
• Personalized treatment approaches may be required to manage residual cardiovascular risk effectively.
• Continuous evaluation of treatment efficacy and safety is essential for optimizing patient outcomes.